Investment Thesis
AnaptysBio demonstrates exceptional revenue growth of 157% YoY with strong liquidity and positive free cash flow, indicating successful commercialization of its pharmaceutical portfolio. However, the company remains unprofitable with negative net margin of -5.6% and declining equity value, raising concerns about cost structure and path to sustainable profitability despite impressive top-line growth.
ANAB Strengths
- Exceptional revenue growth of 157% YoY indicating strong market demand and successful product commercialization
- Fortress balance sheet with $238.2M cash and 9.07x current ratio providing substantial financial flexibility
- Positive free cash flow generation of $19.6M with 8.4% FCF margin despite negative net income, suggesting operational efficiency
- Improving profitability trend with net loss narrowed 90.9% YoY, showing trajectory toward breakeven
ANAB Risks
- Company remains unprofitable with -$13.2M net income and negative ROE (-35.6%) and ROA (-3.6%) indicating shareholder value destruction
- Significant divergence between operating income ($47.9M positive) and net income (-$13.2M negative) suggests material non-operating expenses or charges requiring clarification
- Stockholders' equity eroded to $37.2M against $364.4M total assets, indicating accumulated losses have substantially diminished equity base
- High insider trading activity with 26 Form 4 filings in 90 days warrants monitoring for potential information asymmetry concerns
Key Metrics to Watch
- Net income trend toward profitability - critical to confirm sustainability of operations
- Gross margin percentage once disclosed - essential to assess underlying unit economics and pricing power
- Operating cash flow sustainability and FCF conversion ratio - verify whether positive cash generation persists
- Stockholders' equity trajectory - monitor whether continued losses further erode capital base
- Operating expense growth rate relative to revenue growth - determine if cost structure is scalable
ANAB Financial Metrics
ANAB Profitability Ratios
ANAB Balance Sheet & Liquidity
ANAB 5-Year Financial Trend
5-Year Trend Summary: ANAPTYSBIO, INC's revenue has grown significantly by 213% over the 5-year period, indicating strong business expansion. The most recent EPS of $-6.08 indicates the company is currently unprofitable.
ANAB Growth Metrics (YoY)
ANAB Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $30.0M | $15.1M | $0.52 |
| Q2 2025 | $11.0M | -$38.6M | $-1.34 |
| Q1 2025 | $7.2M | -$39.3M | $-1.28 |
| Q3 2024 | $3.3M | -$32.9M | $-1.14 |
| Q2 2024 | $3.5M | -$39.8M | $-1.50 |
| Q1 2024 | $1.4M | -$43.9M | $-1.58 |
| Q3 2023 | $1.3M | -$32.6M | $-1.18 |
| Q2 2023 | $1.2M | -$32.6M | $-1.15 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
ANAB Capital Allocation
ANAB SEC Filings
Access official SEC EDGAR filings for ANAPTYSBIO, INC (CIK: 0001370053)